Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn has signed an exclusive supply agreement with PrimaPharm to supply Hydase indicated as an adjuvant to increase the absorption and dispersion of other injected drugs.
Subscribe to our email newsletter
Hydase will be manufactured by PrimaPharm, which owns its new drug application. Hydase' formulation is preservative free and does not contain thimerosal, a mercury-containing agent. Akorn will have exclusive marketing and distribution rights in the US and Puerto Rico, and expects to launch the product in the first half of 2007.
The total US market size for Hyaluronidase Injection is $8.6 million, according to 2006 IMS data.
“This is a niche, NDA product that fits our marketing strategy in both our hospital and ophthalmic business segments. The fact that Hydase does not contain thimerosal is an important competitive advantage over other marketed hyaluronidase drugs,” said Arthur Przybyl, Akorn's president and CEO.